Impact of Pre‐Treatment Serum Ferritin on Response and Survival in Myelodysplastic Syndromes Treated With Azacytidine: A Multivariate Analysis
Cancer Medicine · 2025
DOI: 10.1002/cam4.71127 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Gloria Moreno Carrasco und 8 weiteren Autor:innen. Beteiligte Einrichtung: UGC Hematología y Hemoterapia, Hospital Universitario Virgen de la Victoria, Málaga, Spain. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Ferritins, Azacitidine, Antimetabolites, Antineoplastic. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Myelodysplastic syndromes (MDS) encompass a heterogeneous group of haematological neoplasms characterized by ineffective haematopoiesis and a variable risk of transformation to acute myeloid leukaemia (AML). Elevated serum ferritin (SF), a marker of iron overload (IO), has been linked to poorer outcomes in MDS. However, the impact of pre‐treatment SF levels on azacytidine (AZA) response and survival outcomes remains unclear.
Methods
This retrospective cohort study included patients with World Health Organization‐defined MDS or AML with 20%–30% bone marrow blasts treated with AZA at the Virgen de la Victoria University Hospital (Málaga, Spain) from 2007 onwards. Patients were stratified into three groups based on pre‐treatment SF levels: < 500 ng/mL, 500–1000 ng/mL and > 1000 ng/mL. Logistic regression and Kaplan–Meier methods were used to analyse overall response (OR) and overall survival (OS).
Results
Among 240 patients, 190 with available SF data were analysed. Patients with SF > 1000 ng/mL showed significantly lower OR (24.2%) and shorter OS (median: 10.1 months) compared to those with SF < 500 ng/mL (OR: 71.4%, OS: 18.2 months) and 500–1000 ng/mL (OR: 82.6%, OS: 20.5 months) ( p < 0.0001 for OR, p = 0.001 for OS). Multivariate analysis confirmed elevated SF as an independent predictor of poorer outcomes.
Conclusions
Elevated pre‐treatment SF levels are strongly associated with reduced response and survival in patients with MDS or AML treated with AZA. Early IO management, such as iron chelation, may improve treatment outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UGC Hematología y Hemoterapia, Hospital Universitario Virgen de la Victoria, Málaga, Spain.
- BE21-Hematología e Inmunoterapia, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (IBIMA Plataforma BIONAND), Málaga, Spain.
- Departamento de Fisiología Humana, Histología Humana, Anatomía Patológica y Educación Físico-Deportiva, Facultad de Medicina, Universidad de Málaga, Málaga, Spain.
- UGC Farmacia, Hospital Universitario Virgen de la Victoria, Málaga, Spain.
ORCID-Profile: Rodolfo Matias Ortiz Flores, Alejandro Escamilla-Sánchez
Zitieren
APA
Carrasco, G. M., Flores, R. M. O., Delgado, R. G., Morcillo, B. C., Rosell Mas, A. I., Díaz Canales, D., González, M. R., Gomariz, M. C., & Escamilla-Sánchez, A. (2025). Impact of Pre‐Treatment Serum Ferritin on Response and Survival in Myelodysplastic Syndromes Treated With Azacytidine: A Multivariate Analysis. Cancer Medicine. https://doi.org/10.1002/cam4.71127
Vancouver
Carrasco GM, Flores RMO, Delgado RG, Morcillo BC, Rosell Mas AI, Díaz Canales D, et al. Impact of Pre‐Treatment Serum Ferritin on Response and Survival in Myelodysplastic Syndromes Treated With Azacytidine: A Multivariate Analysis. Cancer Medicine. 2025. doi:10.1002/cam4.71127
BibTeX
@article{Carrasco2025,
author = {Carrasco, Gloria Moreno and Flores, Rodolfo Matias Ortiz and Delgado, Regina García and Morcillo, Borja Cidoncha and Rosell Mas, Ana Isabel and Díaz Canales, Dana and González, María Rodríguez and Gomariz, Manuel Carrasco and Escamilla-Sánchez, Alejandro},
title = {Impact of Pre‐Treatment Serum Ferritin on Response and Survival in Myelodysplastic Syndromes Treated With Azacytidine: A Multivariate Analysis},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.71127}
}
EUVIMED